Read by QxMD icon Read

cytotec induction

Daniele Bolla, Saskia Vanessa Weissleder, Anda-Petronela Radan, Maria Luisa Gasparri, Luigi Raio, Martin Müller, Daniel Surbek
BACKGROUND: Misoprostol vaginal insert for induction of labor has been recently reported to be superior to dinoprostone vaginal insert in a phase III trial, but has never been compared to vaginal misoprostol in another galenic form. The aim of this study was to compare misoprostol vaginal insert (MVI) with misoprostol vaginal tablets (MVT) for induction of labor in term pregnancies. METHODS: In this retrospective cohort study we compared 200 consecutive women induced with 200-μg misoprostol 24-h vaginal insert (Misodel®) with a historical control of 200 women induced with Misoprostol 25-μg vaginal tablets (Cytotec®) every 4-6 h...
May 10, 2018: BMC Pregnancy and Childbirth
Shadi Rezai, Pameela Bisram, Isamarie Lora Alcantara, Ruchi Upadhyay, Carla Lara, Malvina Elmadjian
Background. Mullerian duct anomalies (MDAs) are congenital defects of the female genital system that arise from abnormal embryological development of the Mullerian ducts. A didelphys uterus, also known as a "double uterus," is one of the least common amongst MDAs. This report discusses a case of didelphys uterus that successfully conceived, carried her pregnancy to term, and delivered vaginally without any significant complications. Case. Patient is a 29-year-old G2P0010 from Bangladesh, initially came a year prior in her first pregnancy, with spontaneous abortion (SAB)...
2015: Case Reports in Obstetrics and Gynecology
Alexander di Liberto, Jan Endrikat, Sandra Frohn, Erich Solomayer, Kubilay Ertan
OBJECTIVE: Serious fetal malformations and/or chromosome aberrations detected by modern diagnostic tools in early pregnancy require discussions on induced abortion with pregnant women. Competent counseling includes prediction of the time needed for the whole abortion process. In an attempt to refine our predictions, we evaluated the impact of 11 medical history and clinical variables on time to delivery. MATERIAL AND METHODS: We performed a retrospective chart analysis on 79 women submitted for pre-term abortion because of fetal anomalies...
2014: Journal of the Turkish German Gynecological Association
Debora Diniz, Marcelo Medeiros
This paper presents the results of the structured interview phase of the National Abortion Survey (PNA-interviews), describing the itineraries, methods and social and demographic profile of women who had at least one illegal abortion. Structured interviews were conducted during the years 2010 and 2011 in five state capitals (Belem, Brasilia, Porto Alegre, Rio de Janeiro and Salvador) with 122 women aged between 18 and 39 who had abortions. It is a non-probabilistic sample controlled by six parameters in accordance with level of education and age to reflect the social and demographic structure found in the PNA ballot-box questionnaire phase...
July 2012: Ciência & Saúde Coletiva
Haikel Trabelsi, Nabil Mathlouthi, Sonia Zayen, Mohamed Dhouib, Kaies Chaabene, Khaled Trabelsi, Habib Amouri, Belhassen Ben Ayed, Mohamed Guermazi
AIM: To compare the efficacy and safety of cervical ripening at term by vaginal Misoprostol and Dinoprostone. METHODS: We performed a prospective randomized study on cervical ripening with misoprostol and dinoprostone in the third trimester of pregnancy. 300 patients have been divided into two groups: one consisted by 150 patients who received Misoprostol (Cytotec ®) and the second consisted by 150 patients who received Dinoprostone (Prépidil ®). RESULTS: Analysis of our results allowed to reveal: a significant decrease in the time of entry into work for the Misoprostol group (9...
May 2012: La Tunisie Médicale
Ellen L Mozurkewich, Julie L Chilimigras, Deborah R Berman, Uma C Perni, Vivian C Romero, Valerie J King, Kristie L Keeton
BACKGROUND: Rates of labour induction are increasing. We conducted this systematic review to assess the evidence supporting use of each method of labour induction. METHODS: We listed methods of labour induction then reviewed the evidence supporting each. We searched MEDLINE and the Cochrane Library between 1980 and November 2010 using multiple terms and combinations, including labor, induced/or induction of labor, prostaglandin or prostaglandins, misoprostol, Cytotec, 16,16,-dimethylprostaglandin E2 or E2, dinoprostone; Prepidil, Cervidil, Dinoprost, Carboprost or hemabate; prostin, oxytocin, misoprostol, membrane sweeping or membrane stripping, amniotomy, balloon catheter or Foley catheter, hygroscopic dilators, laminaria, dilapan, saline injection, nipple stimulation, intercourse, acupuncture, castor oil, herbs...
2011: BMC Pregnancy and Childbirth
G Justus Hofmeyr, A Metin Gülmezoglu, Cynthia Pileggi
BACKGROUND: Misoprostol (Cytotec, Searle) is a prostaglandin E1 analogue widely used for off-label indications such as induction of abortion and of labour. This is one of a series of reviews of methods of cervical ripening and labour induction using standardised methodology. OBJECTIVES: To determine the effects of vaginal misoprostol for third trimester cervical ripening or induction of labour. SEARCH STRATEGY: The Cochrane Pregnancy and Childbirth Group's Trials Register (November 2008) and bibliographies of relevant papers...
October 6, 2010: Cochrane Database of Systematic Reviews
Yunus Cetin, Hasan C Macun, Hakki B Beceriklisoy, Sabine Schäfer-Somi, Selim Aslan
The goal of this study was to compare three different medications for the induction of abortion in bitches between day 22 and 40 after mismating, to reduce the dosage and frequency of PGF2alpha applications and to investigate the effects of additional intravaginal applications of misoprostol, a PGE1 analog. For this purpose, 22 bitches of different breeds were assigned to three groups: group 1 (n = 6) received cabergoline (Galastop, 10 microg/kg daily, po) until abortion was complete (first application = day 0) and one administration of alfaprostol (Gabbrostim, 10 microg/kg at day 3, s...
May 2010: Berliner und Münchener Tierärztliche Wochenschrift
S Bozhinova
UNLABELLED: Cytotec (Misoprostol) is a prostaglandin E1 9(PgE1) analogue. Despite that it is not officially registered for obstetric and gynaecological targets, Cytotec (C) is widely used in this sphere. The author aims to study the effect and results from C application used for delivery (birth) induction, as well as means for cervical maturation. In order to reach this aim, beside the group of 45 pregnant women to who we applied C, we also reviewed the existing literature, which reported proves for C efficacy, pharma-kynetics and the safe aspects of its application (usage) in pregnancy...
2007: Akusherstvo i Ginekologii︠a︡
Bechir Khemiri, Afef Ben Slama, Abdelkhalek Hsini, Mohamed Bedis Chennoufi, Ezzedine Sfar, H Chelli, Mourad Bouchnak, Hayene Maghrebi
BACKGROUND: Therapeutic interruption of the pregnancies of the 2nd and 3-rd quarter is often badly accepted by the patients and it is original that his realization is easy, effective and the less traumatic possible. In this indication, the sulprostone (Nalador) is a big contribution. AIM: The purpose of our study is to review this product, to describe our experience concerning its use in the therapeutic interruptions of pregnancies and to study alternatives in case of failure or of against indication in its use...
May 2007: La Tunisie Médicale
Mary Lou Moore
Misoprostol (Cytotec) is a synthetic prostaglandin E1 analogue that was designed for the prevention and treatment of peptic ulcer associated with the use of nonsteroidal anti-inflammatory drugs. In obstetrics, misoprostol has been administered for induction of first and second trimester abortion, for induction of labor in the third trimester, and to control postpartum hemorrhage. None of these uses has been approved by the Food and Drug Administration. Nevertheless, misoprostol is widely used in the United States and throughout the world...
2002: Journal of Perinatal Education
V Porozhanova, D Sampat, K Porozhanova
UNLABELLED: Misoprostol (Cytotec) is a synthetic analogue of PGE1, not yet registered for Obstetric practice. Vowing to its low cost and high efficacy there is marked interest towards this medicament. MATERIALS AND METHODS: 47 patients with induction of labour are distributed into two groups: Gr.A (n = 25), receiving Misoprostol and Gr.B (n = 22) with Oxytocin in perfusion. RESULTS: Protocol of treatment with PGE, includes 50 microg per os every 2 hrs...
2005: Akusherstvo i Ginekologii︠a︡
U Menakaya, V Otoide, L Omo Aghoja, L Omo Agboja, K Odunsi, F Okonofua
The aim of this study was to determine the effectiveness and safety of misoprostol (cytotec, Searle) used during labour in women with missed abortion in the second trimester of pregnancy. Labour was induced in 42 women with missed abortion at the Women's Health and Action Research Centre, Benin City, Nigeria with intermittent vaginal administration of 100 microg tablets of misoprostol every 6 h. All women achieved successful vaginal delivery with five women requiring post-delivery uterine evacuation. The gestational ages of the women at the time of induction ranged between 13-24 weeks with a median of 17 weeks...
August 2005: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
Zh Koleva, M Iankov, A Katsulov, S Savova
The authors induct the labor of 88 pregnant women by Misoprostol /Cytotec/ tablette 50 mcgr accepted every four hour per vaginam. The results are the same as/or better/ than the results per os. Our results are in agreement with experimental one of R.-U. Khan et al,. 2004, fig. 1.
2005: Akusherstvo i Ginekologii︠a︡
O A Adeniji, A Oladokun, O Olayemi, O I Adeniji, A A Odukogbe, O Ogunbode, C O Aimakhu, A O Omigbodun, A O Ilesanmi
The object of this study was to compare the effectiveness of the intravaginal Misoprostol and transcervical Foley catheters as pre-induction cervical ripening agents, to estimate the proportion of patients achieving vaginal delivery and to compare the complications of labour and foetal outcome between the two groups. The study was a prospective, randomised study of pregnant women, with singleton pregnancies who presented for antenatal care and delivery at the University College Hospital (UCH), Ibadan, Nigeria...
February 2005: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
Marsden Wagner
No abstract text is available yet for this article.
2003: Midwifery Today with International Midwife
Alisa B Goldberg, Deborah A Wing
Misoprostol (Cytotec) is safe and effective for induction of labor, although it is not approved by the Food and Drug Administration (FDA) for use in pregnancy. In August 2000, the manufacturer of misoprostol warned against its use in pregnancy because of its abortifacient properties and cited reports of maternal and fetal deaths when misoprostol was used to induce labor, fueling the misoprostol controversy. More than 45 randomized trials including more than 5400 women have found vaginal misoprostol to be more effective than oxytocin or vaginal prostaglandin E2 at effecting vaginal delivery within 24 hours...
July 2003: Journal of Midwifery & Women's Health
N Milchev, B Kuzmanov, R Terzhumanov
OBJECTIVE: Our purpose was to compare the safety and efficacy of intravaginal Cytotec versus Oxytocin for induction of labor. STUDY DESIGN: Two hundredth seventy six of patients with indications for induction of labor were assigned to receive either intravaginal Cytotec or Oxytocin. Cytotec were placed in the posterior vaginal fornix every three (3) hours with a potential maximum of six (6) doses. Oxytocin were administered to a standard protocol of our clinic. RESULTS: Among those evaluated 138 received Cytotec and 137 received Oxytocin...
2003: Akusherstvo i Ginekologii︠a︡
(no author information available yet)
On April 17, 2002, the U.S. Food and Drug Administration approved a new label for the use of Cytotec (misprostol) during pregnancy. The new labeling does not contain claims regarding the efficacy and/or safety of Cytotec when it is used for cervical ripening for the induction of labor nor does it stipulate doses or dosing intervals. Therefore, the Committee on Obstetric Practice reminds Fellows that this agent should be used as previously recommended.
July 2003: International Journal of Gynaecology and Obstetrics
(no author information available yet)
On April 17, 2002, the U.S. Food and Drug Administration approved a new label for the use of Cytotec (misoprostol) during pregnancy. The new labeling does not contain claims regarding the efficacy and/or safety of Cytotec when it is used for cervical ripening for the induction of labor nor does it stipulate doses or dosing intervals. Therefore, the Committee on Obstetric Practice reminds Fellows that this agent should be used as previously recommended.
May 2003: Obstetrics and Gynecology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"